stable-phased COPD
Conditions
Interventions
Sponsors
The First Affliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. patients meeting the diagnostic criteria for COPD, who is in stable situation, or hospitalized patients because of acute exacerbation entering the stable phase after standard treatment; 2. patients aged 40-80 years old; 3. patients who can go to the hospital for treatment; 4. patients who have symptoms of COPD, such as cough, sputum, shortness of breath,etc; 5. patients who accept standardizedmedical treatment plan provided by respiratory physician.
Exclusion criteria
Exclusion criteria: 1. Patients suffering from diabetes whose glycemic control are not satisfied; 2. patients suffering from peripheral vascular disease (thromboangiitis obliterans, arteriosclerosis obliterans, lower extremity arterial thrombosis, varicose veins, etc.); 3. patients suffering from lower limb joint diseases which affect the activities; 4. patients suffering from cerebrovascular disease sequelae limb movement disorder; 5. patients who undergoes unstable angina within one month, suffering from acute myocardial infarction within six months; 6. patients suffering from severe arrhythmia; 7. patients suffering from severe heart failure; 8. patients suffering from high blood pressure whose blood pressure control is not satisfied (systolic blood pressure> 160 mmHg and/or diastolic blood pressure > 100mmHg) and chronic liver and kidney dysfunction; 9. patients suffering from cognitive impairment and mental disorders, and other diseases that can affect movement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VE/VCO2;mMRC;METS;FVC;GOLD;VO2/Kg%pred;FEV1;MEF25%;6MWD;MEF50%;FEV1/FVC%;VEmax;MVV;VE/VO2;VO2/HR%;COPD assessment test;MEF75%;VE; | — |
Secondary
| Measure | Time frame |
|---|---|
| muscular mTOR;serum IL-10;Regular blood test;serum IL-1;muscular MyoD;muscular IGF-1;serum TNF-alpha;Blood gas analysis;muscular MURF-1;muscular atrogin-1;muscular AKT; | — |
Countries
China
Contacts
Public ContactYing He
Outcome results
None listed